News

©BillionPhotos/Shuttersstock.com

Rheumatoid arthritis patients treated with mavrilimumab had significantly reduced disease activity and greater ARC20 response compared to placebo in phase IIB study.

(Psoriasis ©ChristineLangerPueschel/Shutterstock.com)

The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.